Strengthened balance sheet during the first quarter of 2021 with the closing of two direct offerings totaling $22.8 million in gross proceeds and $3.3 million from the exercise of warrants…
Read More
– Dr. Douglas Lind brings over 30 years of healthcare and capital markets experience to the board – NEW YORK, March 18, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first…
Read More
NAPLES, Fla., March 15, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David…
Read More
– License has the Potential to Expand Enveric’s Planned Capabilities to Address Cancer Treatment Side Effects – – Innovative Conjugation Platform Aims to Provide Superior Therapeutic Outcomes for Patients by…
Read More
Enveric and PureForm to Develop High-Quality, Consistent, Pure CBD Formulations and Delivery Technology for Treating Pain and Inflammation Resulting from Cancer Treatments NAPLES, Fla., Feb. 25, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or…
Read More
NAPLES, Fla., Feb. 12, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients,…
Read More
NAPLES, Fla., Feb. 9, 2021 — Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients,…
Read More
Advancing pipeline with naturally occurring and synthetic compounds initially focused on the development of cannabinoids for pharmaceutical use Enveric has assembled a highly accomplished executive team, Board of Directors and…
Read More
NAPLES, Fla., Jan. 15, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing…
Read More
NAPLES, Fla., Jan. 12, 2021 — Enveric Biosciences Inc. (NASDAQ: ENVB), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that it…
Read More
